PMID- 38540209
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 12
IP  - 3
DP  - 2024 Mar 7
TI  - Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients 
      with Treatment-Resistant Schizophrenia.
LID - 10.3390/biomedicines12030597 [doi]
LID - 597
AB  - Managing schizophrenia with clozapine poses a significant challenge due to 
      prevalent therapeutic failures. The increasing interest in personalized medicine 
      underscores the importance of integrating pharmacogenetic information for 
      effective pharmacotherapeutic monitoring in patients. The objective of this study 
      was to explore the correlation between DRD2, HTR2A, SLC6A4, CYP1A2, and ABCB1 
      polymorphisms and clozapine response in 100 patients with Treatment-Resistant 
      Schizophrenia. Different scales such as the Positive and Negative Syndrome Scale 
      (PANSS), the Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS), the Global 
      Assessment of Functioning Scale (GAF), the Brief Negative Symptom Scale (BNSS), 
      and pharmacokinetic parameters were used to analyse the efficacy of the 
      treatment. Patients who exclusively responded to clozapine compared to the 
      patients with augmentation strategies exhibited distinctive features, such as 
      lower doses, plasma levels, and presented less-pronounced symptomatology. Genetic 
      associations were explored, highlighting SLC6A4, HTR2A, and the *1F/*1F 
      polymorphism for the CYP1A2 gene.
FAU - Sanguesa, Estela
AU  - Sanguesa E
AUID- ORCID: 0000-0002-3818-4488
AD  - Facultad de Ciencias de la Salud, Universidad San Jorge, Villanueva de Gallego, 
      E-50830 Zaragoza, Spain.
FAU - Fernandez-Egea, Emilio
AU  - Fernandez-Egea E
AUID- ORCID: 0000-0003-4128-8955
AD  - Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge CB21 5EF, UK.
AD  - Department of Psychiatry, Behavioural and Clinical Neuroscience Institute, 
      University of Cambridge, Cambridge CB2 0SZ, UK.
FAU - Concha, Julia
AU  - Concha J
AUID- ORCID: 0000-0002-6990-8127
AD  - Facultad de Ciencias de la Salud, Universidad San Jorge, Villanueva de Gallego, 
      E-50830 Zaragoza, Spain.
FAU - Garcia, Cristina B
AU  - Garcia CB
AUID- ORCID: 0000-0002-9036-3483
AD  - Facultad de Ciencias de la Salud, Universidad San Jorge, Villanueva de Gallego, 
      E-50830 Zaragoza, Spain.
FAU - Ribate, Maria Pilar
AU  - Ribate MP
AUID- ORCID: 0000-0002-1466-0179
AD  - Facultad de Ciencias de la Salud, Universidad San Jorge, Villanueva de Gallego, 
      E-50830 Zaragoza, Spain.
LA  - eng
GR  - Research Group B58_23R/Gobierno de Aragon/
PT  - Journal Article
DEP - 20240307
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC10967865
OTO - NOTNLM
OT  - antipsychotics
OT  - drug response
OT  - genetic testing
OT  - pharmacodynamics
OT  - pharmacogenetic variants
OT  - treatment-resistant schizophrenia
COIS- E.F.-E. has received consultancy honoraria from Boehringer-Ingelheim (2022), 
      Atheneum (2022) and Rovi (2022), speaker fees by Adamed (2022) and Otsuka (2023) 
      and training and research material from Merz (2020). The remaining authors 
      declare that the research was conducted in the absence of any commercial or 
      financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2024/03/28 06:45
MHDA- 2024/03/28 06:46
PMCR- 2024/03/07
CRDT- 2024/03/28 01:06
PHST- 2024/01/31 00:00 [received]
PHST- 2024/02/28 00:00 [revised]
PHST- 2024/03/05 00:00 [accepted]
PHST- 2024/03/28 06:46 [medline]
PHST- 2024/03/28 06:45 [pubmed]
PHST- 2024/03/28 01:06 [entrez]
PHST- 2024/03/07 00:00 [pmc-release]
AID - biomedicines12030597 [pii]
AID - biomedicines-12-00597 [pii]
AID - 10.3390/biomedicines12030597 [doi]
PST - epublish
SO  - Biomedicines. 2024 Mar 7;12(3):597. doi: 10.3390/biomedicines12030597.